Poster

  • eP154

Anfängliche Wirksamkeit und Sicherheit von RP1+ Nivolumab bei Patienten mit Anti-PD-1-fehlgeschlagenem Melanom aus der laufenden Phase-1/2-Studie IGNYTE

Presented in

Selbststudium: Melanom: Immuntherapie

Poster topics

Authors

Prof. Dr. Dirk Schadendorf (Essen), Bartosz Chmielowski (Los Angeles, CA, US), Mohammed M. Milhem (Iowa City, US), Joseph J. Sacco (Wirral, GB; Liverpool, GB), Tawnya Lynn Bowles (Murray, US), Katy K. Tsai (San Francisco, CA, US), Gino K. In (Los Angeles, CA, US), Eva Muñoz-Couselo (Barcelona, ES), Ari M. VanderWalde (Germantown, US), Jason Alan Chesney (Louisville, US), Judith Michels (Villejuif, FR), Adel Samson (Leeds, GB), Georgia M. Beasley (Durham, US), Fade Mahmoud (Gilbert, US), Michael K. Wong (Houston, US), Trisha M. Wise-Draper (Cincinnati, US), Junhong Zhu (Woburn, US), Praveen K. Bommareddy (Woburn, US), Walter Hong (Woburn, US), Jeannie W. Hou (Woburn, US), Mark R. Middleton (Oxford, GB)

  • © Conventus Congressmanagement & Marketing GmbH